Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

European Parliament calls for curtailing of animal and plant breeding patents (Out-Law) (IP Watch)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

(WHO donors) Gates Foundation, US, UK, Canada, Rotary Int., Norway and GAVI: Setting the agenda for global public health? (KEI)

TRIPS and access to medicines in developing countries: is it a matter of law or a matter of corporate responsibility? (Kluwer Patent Blog)

Agenda of TRIPS Council meeting (5-6 June 2012): Information exchange on counterfeits, WIPO negotiations on copyright L&Es (KEI)

G8 countries take hard line on counterfeit medicines (IP Watch)

Asian governments plan to better use TRIPS flexibilities for health (IP Watch)

Australia ‘gene patents’ debate: lies, damn lies, and statistics (Patentology)

Brazil: Manguezais de Alagoas geographical indication granted for propolis, commonly used in the pharmaceutical sector (IP tango)

Denmark: Maritime and Commercial Court upholds of patent claiming second medical use of a known compound (Kluwer Patent Blog)

European Parliament calls for curtailing of animal and plant breeding patents (Out-Law) (IP Watch)

UK: Patents will not be granted to inventions that result from human embryo destruction, IPO says (Out-Law)

US: FTC Commissioner objects to certain provisions in Senate FDA User Fee Reauthorization Legislation (FDA Law Blog)

US: House passes User Fee Bill (H.R. 5651) (Patent Docs) (FDA Law Blog)

US: Recent ICE Press regarding counterfeit of pharmaceutical drugs (KEI)

US: Man gets three years probation, no jail time, for importing counterfeit drugs into USA (KEI)

US: “Suggestion” of mootness or, alternatively, motion for remand in AMP v. USPTO (Patent Docs)

US: Challenging the USPTO’s patent term adjustment calculations for RCEs: Exelixis v Kappos and Human Genome Sciences v Kappos (Pharma Patents)

US: Settlement does not justify vacating summary judgment of noninfringement: EMD Crop Bioscience v Becker Underwood (Docket Report)

US: Panagene files patent infringement suit against Bio-Synthesis over peptide nucleic acids (Patent Docs)

US: Exelixis seeks correction of PTA calculation concerning “c-Met Modulators and Methods of Use” patent (Patent Docs)

 

Products

Adenoscan (Adenosine) – US: Astellas files patent infringement suit against Hospira in response to Para IV challenge (Patent Docs)

Copaxone (Glatiramer acetate) – UK: EWCA (Civ): In-house patent attorney who previously worked for the opposing side allowed to work on litigation: Generics (UK) v Yeda Research & Development (IPKat)

Exelon (Rivastigmine) – Israel: Is a patent applicant obliged to make clinical trials available to prove the efficiacy and non-obviousness of an invention?: Unipharm opposes Novartis’s application for “New Controlled Release Formulations of Rivastigmine” (The IP Factor)

Lialda (Mesalamine) – US: Shire files patent infringement complaint against Mylan in response to Para IV challenge (Patent Docs)

Sustiva (Efavirenz) – UK: Silence speaks a thousand words: EWHC (Pat) grants interim injunction in Merck Sharp Dohme Corp and Bristol -Myers Squibb v Teva (PatLit)

Testim (Testosterone) – US: Auxilium files patent infringement suit against Watson in response to Para IV challenge (Patent Docs)

Torisel (Temsirolimus) – US: Pfizer files patent infringement suit against Sandoz in response to Para IV cerfication (Patent Docs)

Tri-Cyclen Lo (Norgestimate, Ethinyl estradiol) – US: Janssen Pharmaceuticals files patent infringement suit against Haupt Pharma in response to Para IV certification filing (Patent Docs)

Wellbutrin (Bupropion)– US: Pennsylvania District Court issues an XL decision in Wellbutrin XL antitrust, sham citizen petition case (FDA Law Blog)